Published in Am J Respir Crit Care Med on September 13, 2007
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 8.36
T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med (2009) 7.11
Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med (2012) 4.85
The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest (2008) 3.90
Eosinophils: changing perspectives in health and disease. Nat Rev Immunol (2012) 2.69
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 2.24
A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci U S A (2009) 2.16
Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J Exp Med (2008) 2.11
Innate cells and T helper 2 cell immunity in airway inflammation. Immunity (2009) 1.94
Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration (2009) 1.92
Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol (2015) 1.70
Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol (2009) 1.43
Eosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge. J Allergy Clin Immunol (2014) 1.43
What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol (2010) 1.33
Many cytokines are very useful therapeutic targets in disease. J Clin Invest (2008) 1.33
Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol (2010) 1.32
Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev (2011) 1.29
Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy (2014) 1.29
The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med (2007) 1.24
A new look at the pathogenesis of asthma. Clin Sci (Lond) (2009) 1.22
Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. Ann Intern Med (2010) 1.13
The potential of biologics for the treatment of asthma. Nat Rev Drug Discov (2012) 1.11
Therapeutic options for severe asthma. Arch Med Sci (2012) 1.11
Cytokine/anti-cytokine therapy - novel treatments for asthma? Br J Pharmacol (2011) 1.11
Combined sensitization of mice to extracts of dust mite, ragweed, and Aspergillus species breaks through tolerance and establishes chronic features of asthma. J Allergy Clin Immunol (2009) 1.05
Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov (2015) 1.05
Immunomodulation of allergic disease. Annu Rev Med (2009) 1.02
Murine lung eosinophil activation and chemokine production in allergic airway inflammation. Cell Mol Immunol (2010) 1.01
Differential microRNA epression in asthma and the role of miR-1248 in regulation of IL-5. Am J Clin Exp Immunol (2012) 1.01
Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci (2011) 1.00
Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines. Respir Res (2010) 1.00
Stratified approaches to the treatment of asthma. Br J Clin Pharmacol (2013) 0.98
IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J Allergy Clin Immunol (2012) 0.96
Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One (2013) 0.95
Galectin-3: its role in asthma and potential as an anti-inflammatory target. Respir Res (2013) 0.93
Virus/allergen interactions in asthma. Curr Allergy Asthma Rep (2013) 0.93
Update on anticytokine treatment for asthma. Biomed Res Int (2013) 0.92
Targeting eosinophils in asthma. Curr Mol Med (2008) 0.91
Current concepts of severe asthma. J Clin Invest (2016) 0.91
Eosinophils: offenders or general bystanders in allergic airway disease and pulmonary immunity? J Innate Immun (2011) 0.90
Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract (2015) 0.90
Asthma: eosinophil disease, mast cell disease, or both? Allergy Asthma Clin Immunol (2008) 0.88
Biologics in asthma--the next step toward personalized treatment. J Allergy Clin Immunol Pract (2015) 0.88
IL-3 Maintains Activation of the p90S6K/RPS6 Pathway and Increases Translation in Human Eosinophils. J Immunol (2015) 0.88
The naive airway hyperresponsiveness of the A/J mouse is Kit-mediated. Proc Natl Acad Sci U S A (2011) 0.88
Mast cells and company. Front Immunol (2012) 0.87
Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice. Exp Dermatol (2009) 0.87
Important role of neutrophils in the late asthmatic response in mice. Life Sci (2011) 0.87
Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J (2016) 0.86
Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol (2014) 0.85
Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clin Exp Immunol (2009) 0.85
Monoclonal antibodies and other biologic agents in the treatment of asthma. MAbs (2009) 0.85
How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin Immunol (2009) 0.84
Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol (2011) 0.83
Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma. Clin Dev Immunol (2013) 0.82
Genome-wide association study of the age of onset of childhood asthma. J Allergy Clin Immunol (2012) 0.82
Neuronal modulation of airway and vascular tone and their influence on nonspecific airways responsiveness in asthma. J Allergy (Cairo) (2012) 0.82
Innate immunity is a key factor for the resolution of inflammation in asthma. Eur Respir Rev (2015) 0.82
Recommendation for optimal management of severe refractory asthma. J Asthma Allergy (2010) 0.81
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis (2016) 0.81
Pharmacotherapy of severe asthma. Curr Opin Pharmacol (2010) 0.81
Lebrikizumab in the personalized management of asthma. Biologics (2012) 0.81
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics (2013) 0.81
The immunology of asthma: Asthma phenotypes and their implications for personalized treatment. Ann Allergy Asthma Immunol (2016) 0.81
Unlocking proteomic heterogeneity in complex diseases through visual analytics. Proteomics (2015) 0.81
Anti-IL5 therapy for asthma and beyond. World Allergy Organ J (2014) 0.79
IgE-activated basophils regulate eosinophil tissue entry by modulating endothelial function. J Exp Med (2015) 0.79
Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther (2015) 0.78
Neonatal epithelial hypoxia inducible factor-1α expression regulates the response of the lung to experimental asthma. Am J Physiol Lung Cell Mol Physiol (2011) 0.78
Estrogen Signaling Modulates Allergic Inflammation and Contributes to Sex Differences in Asthma. Front Immunol (2015) 0.78
Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma. Mediators Inflamm (2015) 0.78
The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. J Asthma Allergy (2015) 0.77
Asthma that is unresponsive to usual care. CMAJ (2009) 0.77
Asthma therapies revisited: what have we learned? Proc Am Thorac Soc (2009) 0.77
Antagonism of cytokine-induced eosinophil accumulation in asthma. Front Pharmacol (2012) 0.77
Interaction between allergy and innate immunity: model for eosinophil regulation of epithelial cell interferon expression. Ann Allergy Asthma Immunol (2013) 0.77
Generation of eosinophils from cryopreserved murine bone marrow cells. PLoS One (2014) 0.77
Role of monoclonal antibodies in the treatment of asthma. Can Respir J (2013) 0.77
Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res (2015) 0.76
Biological agents targeting beyond TNF-alpha. Indian J Crit Care Med (2008) 0.76
Update on biological therapeutics for asthma. World Allergy Organ J (2010) 0.76
Severe Asthma: The Evolution of Patient-directed Management. Clin Pulm Med (2014) 0.76
New therapies and management strategies in the treatment of asthma: patient-focused developments. J Asthma Allergy (2010) 0.76
Unusual asthma syndromes and their management. Ther Adv Chronic Dis (2011) 0.75
Defining severe asthma - an approach to find new therapies. Eur Clin Respir J (2014) 0.75
Mepolizumab. Hosp Pharm (2016) 0.75
The transition of sputum inflammatory cell profiles is variable in stable asthma patients. Asia Pac Allergy (2017) 0.75
Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential. Ther Adv Chronic Dis (2016) 0.75
Clinical usefulness of mepolizumab in severe eosinophilic asthma. Ther Clin Risk Manag (2016) 0.75
Eosinophils, galectins, and a reason to breathe. Proc Natl Acad Sci U S A (2016) 0.75
Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
Update on the Management of Aspirin-Exacerbated Respiratory Disease. Allergy Asthma Immunol Res (2016) 0.75
Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer. Curr Allergy Asthma Rep (2012) 0.75
Mepolizumab (Nucala) For Severe Eosinophilic Asthma. P T (2016) 0.75
Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. J Asthma Allergy (2015) 0.75
A Mathematical Modeling Approach to Understanding the Effect of Anti-Interleukin Therapy on Eosinophils. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents. Immunol Allergy Clin North Am (2014) 0.75
Breathing Better Through Bugs: Asthma and the Microbiome. Yale J Biol Med (2016) 0.75
Predictive Biomarkers for Asthma Therapy. Curr Allergy Asthma Rep (2017) 0.75
The Pharmaceutical Industry Needs More Clinical Pharmacologists. Br J Clin Pharmacol (2017) 0.75
The genome of the model beetle and pest Tribolium castaneum. Nature (2008) 6.50
Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol (2005) 4.67
Averting biodiversity collapse in tropical forest protected areas. Nature (2012) 4.46
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol (2011) 3.21
Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest (2003) 3.16
Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol (2010) 3.12
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med (2010) 3.11
The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med (2002) 3.05
Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax (2010) 2.86
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med (2004) 2.81
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol (2005) 2.80
Retracted The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med (2006) 2.72
The mouse trap: It still yields few answers in asthma. Am J Respir Crit Care Med (2006) 2.68
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood (2007) 2.67
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest (2008) 2.38
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med (2013) 2.25
A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A (2002) 2.24
Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol (2004) 2.22
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol (2012) 2.19
Prospects for new drugs for chronic obstructive pulmonary disease. Lancet (2004) 2.17
Soil Respiration in European Grasslands in Relation to Climate and Assimilate Supply. Ecosystems (2008) 2.17
High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol (2013) 2.14
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 2.13
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol (2005) 2.11
Perioperative dexamethasone administration and risk of bleeding following tonsillectomy in children: a randomized controlled trial. JAMA (2012) 2.08
Purine and pyrimidine (P2) receptors as drug targets. J Med Chem (2002) 2.05
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol (2008) 1.95
A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys (2007) 1.90
Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood (2011) 1.88
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med (2011) 1.86
Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med (2004) 1.80
Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest (2008) 1.80
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol (2010) 1.79
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma (2010) 1.79
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 1.78
Methods for the assessment of endobronchial biopsies in clinical research: application to studies of pathogenesis and the effects of treatment. Am J Respir Crit Care Med (2003) 1.77
High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest (2015) 1.74
Comparative genomic analysis of the Tribolium immune system. Genome Biol (2007) 1.74
Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med (2010) 1.68
Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol (2007) 1.63
The management of acute coronary syndrome patients across New Zealand in 2012: results of a third comprehensive nationwide audit and observations of current interventional care. N Z Med J (2013) 1.60
Men who have sex with men: stigma and discrimination. Lancet (2012) 1.58
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov (2007) 1.52
Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol (2013) 1.49
Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest (2006) 1.47
Abdominal insufflation decreases blood loss and mortality after porcine liver injury. J Trauma (2005) 1.47
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol (2013) 1.42
PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol (2008) 1.42
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest (2004) 1.42
Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med (2008) 1.40
Signing and stamping of official veterinary certification. Vet Rec (2009) 1.39
Communication during suspected notifiable disease incidents. Vet Rec (2006) 1.39
Small bowel obstruction and internal hernias after laparoscopic Roux-en-Y gastric bypass. Obes Surg (2003) 1.38
Timing of thrombotic events in patients receiving 2 weeks of clopidogrel therapy post bare metal coronary artery stenting: a New Zealand retrospective study. N Z Med J (2007) 1.38
Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin (2003) 1.36
Safety of bronchoscopy, biopsy, and BAL in research patients with COPD. Chest (2002) 1.29
Large-scale field application of RNAi technology reducing Israeli acute paralysis virus disease in honey bees (Apis mellifera, Hymenoptera: Apidae). PLoS Pathog (2010) 1.29
Acute Coronary Syndrome patients in New Zealand receive less invasive management when admitted to hospitals without invasive facilities. N Z Med J (2004) 1.29
Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil (2002) 1.27
Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol (2005) 1.27
Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests. Am J Respir Crit Care Med (2006) 1.26
Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg (2004) 1.26
Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol (2012) 1.24
Management of patients admitted with an Acute Coronary Syndrome in New Zealand: results of a comprehensive nationwide audit. N Z Med J (2004) 1.24
Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry (2005) 1.23
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem (2008) 1.22
Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med (2010) 1.20
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol (2008) 1.20
Raised troponin in COPD: clinical implications and possible mechanisms. Heart (2012) 1.19
Patients admitted with an acute coronary syndrome (ACS) in New Zealand in 2007: results of a second comprehensive nationwide audit and a comparison with the first audit from 2002. N Z Med J (2010) 1.15
Noninvasive markers of airway inflammation in asthma. Clin Transl Sci (2009) 1.15
The family costs of attending hospital outpatient appointments via videoconference and in person. J Telemed Telecare (2003) 1.14
Neonatal cytokine profile in the airway mucosal lining fluid is skewed by maternal atopy. Am J Respir Crit Care Med (2011) 1.14
Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res (2011) 1.13
Mitochondrial function and dysfunction: an update. J Pharmacol Exp Ther (2012) 1.13
Non-specific interstitial pneumonia in cigarette smokers: a CT study. Eur Radiol (2009) 1.13
Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol (2008) 1.11
Lung imaging in asthmatic patients: the picture is clearer. J Allergy Clin Immunol (2011) 1.10
A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res (2007) 1.10
Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol (2006) 1.09
Management of non ST-elevationacute coronary syndrome patients in New Zealand: a longitudinal analysis. Results from the New Zealand Acute Coronary Syndrome national audits of 2002, 2007 and 2012. N Z Med J (2016) 1.08
Development and function of T helper 1 cells. Adv Immunol (2004) 1.07
Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol (2008) 1.07
The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol (2008) 1.06
The T-shape spreader--an easily constructed instruction for facilitating the sagittal split osteotomy. Br J Oral Maxillofac Surg (2013) 1.06
A novel method for assessing unchallenged levels of mediators in nasal epithelial lining fluid. J Allergy Clin Immunol (2010) 1.05
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
Glucocorticoid-induced osteoporosis: an update on effects and management. J Allergy Clin Immunol (2013) 1.03
Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol (2003) 1.03
TM9SF4 is required for Drosophila cellular immunity via cell adhesion and phagocytosis. J Cell Sci (2008) 1.02